SLC5A2 and heart failure: ("SGLT-2 inhibitor*" OR "sodium-glucose cotransporter 2 inhibitor*" OR "dapagliflozin" OR "empagliflozin" OR "canagliflozin" OR "ertugliflozin" OR "ipragliflozin" OR "luseogliflozin") AND ("heart failure" OR "cardiac failure" OR "congestive heart failure" OR "CHF" OR "left ventricular dysfunction"). Additional keywords used for title screening: Systematic review, meta-analysis,